American Association of Cancer Research: Oxford Nanopore provides updates on generating the most comprehensive insights into cancer genomes

In the coming days at the American Association of Cancer Research meeting, Oxford Nanopore will provide updates to the cancer research community on the newest sequencing techniques that provide the most comprehensive insights into cancer genomes, and host user talks on the application of the technology.

Using Oxford Nanopore sequencing technology, it is possible to resolve variants and epigenetic modifications across the entire genome, target large panels or single genes without PCR, and detect known and novel full-length transcripts — up to single-cell resolution.

As a result, increasing numbers of researchers are applying the technology to cancer genomics and making new discoveries which could have a significant impact for patients in the future.

AACR 2022 Spotlight: The most comprehensive view of the cancer genome

During a Spotlight session at AACR, hear from scientists using nanopore sequencing to access new genomic and transcriptomic insight and gain an unprecedented view of the mechanisms involved in cancer progression and evolution:

• Jeremy Wang, UNC School of Medicine, will discuss how nanopore full-length transcript sequencing has the potential to predict acute leukaemia lineage and improve the accessibility and accuracy of cancer research in low-resource settings in the future.

• Fritz Sedlazeck, Baylor College of Medicine, will share Sniffles2 — a tool for fast SV calling and accurate detection of SVs on germline, somatic and population-level samples.

• Sissel Juul, Oxford Nanopore Technologies, will be presenting on the real-time enrichment of cancer panels using adaptive sampling on nanopore technology.

In the poster hall

There’s more to discover in the poster hall — from personalised tumour monitoring, to assembling extrachromosomal DNA in tumours, and identifying structure variants using targeted approaches.

530 / 5 - UMAP- Personalized lung cancer monitoring platform

Zahra Haider, Linda Köhn, Nicholas Karlowatz, Mikael B. Johansson, Jonas A. Nilsson. Umeå University, Umeå, Sweden, Umeå Univeristy, Umeå, Sweden

Presentation: Sunday, 10th April, 1:30 PM - 5:00 PM (Poster section 32, poster board 5)

2705 Detection and assembly of extrachromosomal DNA in tumors

with nanopore sequencing. Sergey Aganezov, John Beaulaurier, Eoghan

Harrington, Sissel Juul.

Presentation: Tuesday, 12th April, 9:00 AM.-12:30 PM (Poster Section 28 poster board 5)

2704 Resolving clone-and haplotype-specific copy number

variation and DNA methylation in heterogeneous tumors with nanopore

sequencing. Sergey Aganezov, John Beaulaurier, Eoghan Harrington, Sissel Juul.

Presentation: Tuesday, 12th April, 9:00 AM.-12:30 PM (Poster Section 28, poster board 4)

2279 Cas9 based targeted nanopore sequencing helps identify

structural variants in breast cancer genes. Shruti V. Iyer, Melissa Kramer, Sara

Goodwin, W. Richard McCombie.

Presentation: Tuesday, 12th April, 9:00 AM.-12:30 PM (Poster Section 4, poster board 10)

Oxford Nanopore sequencing for cancer research

The genetic underpinnings of cancer are diverse and many types of genomic aberration — from SNVs to SVs, fusion transcripts, and epigenetic modifications (e.g. DNA/RNA methylation) — can cause, contribute to, or indicate disease. As a result, researchers have traditionally relied on multiple techniques to identify and analyse different forms of cancer.

Now, through the facility to generate sequencing reads of any length, including ultra-long reads in excess of 4 Mb that can span complex genomic regions, accurate characterisation of a range of variants including SNVs, SVs, combined with integrated base modification detection and real-time results, nanopore sequencing delivers a streamlined and rapid solution for complete characterisation of cancer samples.

Learn more

Cancer research using nanopore technology

Clinical and cancer research white paper

Genomics England expands use of Oxford Nanopore sequencing in cancer